Trial Profile
A One-year Randomized, Double-blind, Placebo and Active-controlled Parallel Design Safety and Efficacy Comparison of COMBIVENT HFA Inhalation Aerosol to COMBIVENT (CFC) Inhalation Aerosol in Patients With COPD
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 28 Jul 2014
Price :
$35
*
At a glance
- Drugs Ipratropium-bromide/salbutamol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 28 Jul 2014 New trial record